Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HeiLivCa Study: TACE plus sorafenib versus TACE plus placebo before liver transplantation in hepatocellular carcinoma
ISRCTN24081794Phase 3Completed
- Sponsor
- Heidelberg University
- Start
- Nov 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sorafenib and carboplatin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Heidelberg University. Primary endpoint: Time to progression. Started Nov 2008; status: completed.
02
Drugs
sorafenibcarboplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ISRCTN24081794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN24081794.